Page last updated: 2024-12-07

hydroxybenzylisoproterenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Hydroxybenzylisoproterenol (HBI) is a synthetic β-adrenergic receptor agonist that is structurally related to isoproterenol. It is characterized by its potent bronchodilatory and cardio-stimulatory effects. Research has shown that HBI has a higher affinity for β2-adrenergic receptors than β1-adrenergic receptors, making it a preferred choice for treating asthma and other respiratory conditions. However, its use is limited due to its significant cardiac side effects. HBI's synthesis typically involves the reaction of isoproterenol with a substituted benzaldehyde, followed by reduction of the resulting Schiff base. Studies involving HBI focus on understanding its pharmacological properties, particularly its selectivity for different β-adrenergic receptor subtypes, as well as its potential for therapeutic applications. The compound's potent bronchodilatory effects make it a valuable research tool for investigating the mechanisms of β-adrenergic receptor signaling and drug development for respiratory diseases.'

Cross-References

ID SourceID
PubMed CID122310
MeSH IDM0064421

Synonyms (6)

Synonym
64532-93-0
hydroxybenzylisoprenaline
hydroxybenzylisoproterenol
1,2-benzenediol, 4-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)propyl)-
4-(1-hydroxy-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}propyl)benzene-1,2-diol
DTXSID40983161

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Airway responsiveness was measured by the ability of isoproterenol infusions to shift the histamine dose-response curve for airway constriction."( Differential recovery of beta adrenoreceptor antagonist and agonist high affinity binding sites in the guinea-pig lung after irreversible blockade.
Baker, SP; Muther, TF; Nelson, CA; Pitha, J, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (96.15)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (3.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.17 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]